JP2021510733A5 - - Google Patents

Info

Publication number
JP2021510733A5
JP2021510733A5 JP2020558865A JP2020558865A JP2021510733A5 JP 2021510733 A5 JP2021510733 A5 JP 2021510733A5 JP 2020558865 A JP2020558865 A JP 2020558865A JP 2020558865 A JP2020558865 A JP 2020558865A JP 2021510733 A5 JP2021510733 A5 JP 2021510733A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
cycloalkyl
cycloalkenyl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020558865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510733A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/013375 external-priority patent/WO2019140322A1/en
Publication of JP2021510733A publication Critical patent/JP2021510733A/ja
Publication of JP2021510733A5 publication Critical patent/JP2021510733A5/ja
Priority to JP2024015651A priority Critical patent/JP2024099510A/ja
Pending legal-status Critical Current

Links

JP2020558865A 2018-01-12 2019-01-11 がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ Pending JP2021510733A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024015651A JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616831P 2018-01-12 2018-01-12
US62/616,831 2018-01-12
PCT/US2019/013375 WO2019140322A1 (en) 2018-01-12 2019-01-11 Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024015651A Division JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ

Publications (2)

Publication Number Publication Date
JP2021510733A JP2021510733A (ja) 2021-04-30
JP2021510733A5 true JP2021510733A5 (enExample) 2022-02-08

Family

ID=65516716

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020558865A Pending JP2021510733A (ja) 2018-01-12 2019-01-11 がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ
JP2024015651A Pending JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024015651A Pending JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ

Country Status (7)

Country Link
US (2) US12128018B2 (enExample)
EP (1) EP3737362B1 (enExample)
JP (2) JP2021510733A (enExample)
CN (1) CN112135610A (enExample)
CA (1) CA3125731A1 (enExample)
ES (1) ES3057234T3 (enExample)
WO (1) WO2019140322A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
JP2021510733A (ja) 2018-01-12 2021-04-30 ケーディーエーシー セラピューティクス,インコーポレーテッドKdac Therapeutics, Inc. がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ
SG11202009438UA (en) 2018-04-18 2020-11-27 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
CN112262143A (zh) 2018-05-21 2021-01-22 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
PH12022550188A1 (en) 2019-07-24 2022-11-21 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
WO2022251827A1 (en) * 2021-05-24 2022-12-01 H. Lee Moffitt Cancer Center And Research Institute Inc. Immune checkpoint inhibitor and hdac inhibitor combination therapy strategy
US20250000847A1 (en) 2021-09-01 2025-01-02 Case Western Reserve University Treatment of neurodegenerative diseases with hdac inhibitors
CN113754587B (zh) * 2021-09-22 2023-07-14 沈阳药科大学 一种苯基吡唑类化合物及应用
KR20230084416A (ko) * 2021-12-03 2023-06-13 연세대학교 산학협력단 Wnk3 억제제를 유효성분으로 포함하는 면역관문 억제용 조성물

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE670584C (de) 1936-07-09 1939-01-20 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von o-Aminophenolen
DE1108213B (de) 1959-02-28 1961-06-08 Frantisek Sorm Dr Ing Verfahren zur Herstellung von 2, 2-Dimethyl-3-phenylcyclopropan-carbonsaeuren
SE370866B (enExample) 1968-03-21 1974-11-04 Ciba Geigy Ag
JPS4825500B1 (enExample) 1970-12-29 1973-07-30
US3850931A (en) 1971-06-25 1974-11-26 American Home Prod 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters
GB2079480B (en) 1980-07-08 1984-05-16 Kodak Ltd Heat-activated photographic and thermal recording processes employing precursor compounds
NO156828C (no) 1980-11-10 1987-12-02 Otsuka Pharma Co Ltd Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
JPS57102887A (en) 1980-12-18 1982-06-26 Otsuka Pharmaceut Co Ltd Preparation of benzo(ij)quinolizine-2-carboxylic acid derivative
US4404356A (en) 1981-09-09 1983-09-13 Ciba-Geigy Corporation Heat-curable epoxide resin compositions
JPS5853916A (ja) 1981-09-09 1983-03-30 チバ−ガイギ−・アクチエンゲゼルシヤフト 熱硬化性エポキシド樹脂組成物
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
DE3511110A1 (de) 1985-03-27 1986-10-02 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pyridazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel
GB8508588D0 (en) 1985-04-02 1985-05-09 Akzo Nv Indene & napthalene derivatives
NZ219974A (en) 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
DE3830054A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
JPH03232868A (ja) 1990-02-05 1991-10-16 Nippon Telegr & Teleph Corp <Ntt> 新規光学活性化合物及び液晶組成物
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
JPH06122669A (ja) 1991-12-28 1994-05-06 Ishihara Sangyo Kaisha Ltd ジアミノベンゼン誘導体を含有するホスホリパーゼa2阻害剤
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JPH09227495A (ja) 1996-02-16 1997-09-02 Tanabe Seiyaku Co Ltd フェノール誘導体及びその製法
AU8270898A (en) 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
JP4390024B2 (ja) 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
FR2805741B1 (fr) 2000-03-06 2003-06-20 Oreal Composition de teinture d'oxydation des fibres keratiniques avec un derive particulier de la paraphenylenediamine et un colorant direct particulier
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
DE10038007A1 (de) 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
MXPA03005120A (es) 2000-12-07 2004-03-10 Cv Therapeutics Inc Compuestos para el incremento de abca-1.
JP4183923B2 (ja) 2001-03-29 2008-11-19 富士フイルム株式会社 熱現像感光材料
IL157873A0 (en) 2001-04-12 2004-03-28 Hoffmann La Roche DIHYDRO-BENZO [b] [1,4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
ES2384168T3 (es) 2002-04-12 2012-07-02 Medarex, Inc. Procedimientos de tratamiento usando anticuerpos CTLA-4
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
MXPA05008106A (es) 2003-02-18 2005-09-21 Pfizer Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean.
WO2005025557A1 (en) 2003-09-16 2005-03-24 Monash University An agent for plasminogen-activation and matrix metalloproteinase associated conditions and methods of use
CA2539117A1 (en) 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
EP1687513B1 (en) * 2003-10-02 2010-12-22 Jesel, Inc. Double roller cam follower
US7935724B2 (en) 2003-10-09 2011-05-03 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
US20080070954A1 (en) 2003-10-27 2008-03-20 S*Bio Pte Ltd. Acylurea Connected And Sulfonylurea Connected Hydroxamates
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100234409A1 (en) 2004-05-21 2010-09-16 Lihu Yang Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
US20060008517A1 (en) 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
JP4946861B2 (ja) 2004-08-09 2012-06-06 アステラス製薬株式会社 ヒストンデアセチラーゼ(hdac)の阻害活性を有するヒドロキシアミド化合物
WO2006028161A1 (ja) 2004-09-09 2006-03-16 Research Foundation Itsuu Laboratory セロトニン5-ht3受容体作動薬
JP2008546793A (ja) 2005-06-24 2008-12-25 メルク エンド カムパニー インコーポレーテッド 修飾マロン酸誘導体
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CA2635210A1 (en) 2006-01-12 2007-08-02 Merck & Co., Inc. Hydroxyalkylarylamide derivatives
ES2452820T3 (es) 2006-04-07 2014-04-02 Methylgene, Inc. Derivados de benzamida como inhibidores de histona desacetilasa
US20100029615A1 (en) 2006-12-15 2010-02-04 Michael John Munchhof Benzimidazole derivatives
AU2007337088A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
CA2947292C (en) 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
CN103087043A (zh) 2007-03-16 2013-05-08 中国人民解放军军事医学科学院放射与辐射医学研究所 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 pd-1에 대한 항체
EP2170882A1 (en) 2007-06-26 2010-04-07 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
KR20100074288A (ko) 2007-10-22 2010-07-01 오키드 리서치 레버라토리즈 리미티드 히스톤 디아세틸라제 억제제
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
WO2009076234A2 (en) 2007-12-07 2009-06-18 University Of Maryland, Baltimore Synthesis methods of histone deacetylase inhibitors (hdacis)
MY156226A (en) 2008-02-22 2016-01-29 Otsuka Pharma Co Ltd Benzodiazepine compound and pharmaceutical composition
US8093000B2 (en) 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
AU2009271003A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
US20110178138A1 (en) 2008-07-28 2011-07-21 The Regents Of The University Of California Inhibitors of protein prenyltransferases
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
EP2367599A4 (en) 2008-12-03 2012-08-08 Massachusetts Inst Technology HDAC2-INHIBITION FOR MEMORY STRENGTH
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
KR20110117194A (ko) 2009-02-23 2011-10-26 에프. 호프만-라 로슈 아게 암 치료를 위한 신규한 오르토-아미노아미드
EP2432779A1 (en) 2009-05-22 2012-03-28 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
MX2011013294A (es) 2009-06-11 2012-01-12 Siena Biotech Spa Antagonistas de la trayectoria de hedgehog y aplicaciones terapeuticas de los mismos.
EP2454254A2 (en) 2009-07-16 2012-05-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
IN2012DN03807A (enExample) 2009-10-30 2015-08-28 Massachusetts Inst Technology
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US20140107166A1 (en) 2011-02-14 2014-04-17 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
WO2012118750A2 (en) 2011-02-28 2012-09-07 Genentech, Inc. Biological markers and methods for predicting response to b-cell antagonists
JP6250403B2 (ja) * 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
CN102775356B (zh) 2011-05-13 2015-07-22 江苏恒谊药业有限公司 4-氨基喹唑啉衍生物及其应用
WO2013006739A2 (en) 2011-07-05 2013-01-10 Zia Shlaimoun Method and system for video messaging
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013059582A2 (en) 2011-10-20 2013-04-25 Nupotential, Inc. Small molecule inhibitors of histone deacteylases
WO2013067391A1 (en) 2011-11-02 2013-05-10 The Broad Institute, Inc. Fluorescent substrates for determining lysine modifying enzyme activity
CA2759407A1 (en) 2011-12-02 2013-06-02 Marrett Alexander GREEN Grey water recycling systems and valves
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
USRE49240E1 (en) * 2013-11-05 2022-10-11 The General Hospital Corporation Inhibitors of histone deacetylase
US20160346240A1 (en) 2014-02-03 2016-12-01 Quadriga Biosciences, Inc. Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ(lsd1)およびヒストンデアセチラーゼ(hdac)の阻害剤
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3047334A1 (en) * 2017-01-10 2018-07-19 Dana-Farber Cancer Institute, Inc. Compositions and methods using an epigenetic inhibitor
JP2021510733A (ja) 2018-01-12 2021-04-30 ケーディーエーシー セラピューティクス,インコーポレーテッドKdac Therapeutics, Inc. がんの処置のための選択的ヒストンデアセチラーゼ3(hdac3)インヒビターと免疫治療剤との組み合わせ

Similar Documents

Publication Publication Date Title
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
JP2022512156A5 (enExample)
JP2009532486A5 (enExample)
RU2019115392A (ru) Производные тиенопиррола для применения для нацеливания на белки, композиции с указанными производными, способы и применения
CA2405521A1 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
JP2013544812A5 (enExample)
CA2410662A1 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
RU2000117278A (ru) Производное 2-арил-8-оксодигидропурина, способ для его получения, содержащая его фармацевтическая композиция, и промежуточное соединение
BRPI0310094B1 (pt) composto de bis-(monoetanolamina) de ácido 3&#39;-[(2z)-[1-(3,4-dimetilfenil)-1,5-diidro-3-metil-5-oxo-4h-pirazol-4-ilideno]hidrazino]-2&#39;-hidróxi-[1,1&#39;-bifenil]-3-carboxílico, composição farmacêutica e processos para preparar ditos composto e composição farmacêutica
JP2017511360A5 (enExample)
CA2409741A1 (en) Tnf-.alpha. production inhibitors
JP2019504050A5 (enExample)
JP2020122016A5 (enExample)
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
KR920018037A (ko) 4-아릴-티아졸 또는 이미다졸 유도체
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
RU2007108863A (ru) Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3
JP2023538524A5 (enExample)
RU2314292C2 (ru) Производные азетидина в качестве антагонистов ccr-3 рецептора
CA2518224A1 (en) Novel isothiazolopyrimidinones and isoxazolopyrimidinones and uses thereof
RU99125773A (ru) N-триазолил-2-индолкарбоксамиды и их применение в качестве агонистов хцк-а
RU2019128534A (ru) Химические соединения для лечения туберкулеза
JP2021514399A5 (enExample)
CA2553704A1 (en) Substituted benzimidazoles and their use for inducing apoptosis
RU2004111787A (ru) Ретиноидные агонисты (1), производные алкилмочевины